Patel Dharmendrakumar A, Srinivasan Sathanur R, Xu Ji-Hua, Chen Wei, Berenson Gerald S
Tulane Center for Cardiovascular Health, Tulane University Health Science Center, New Orleans, LA 70112, USA.
Metabolism. 2006 Nov;55(11):1551-7. doi: 10.1016/j.metabol.2006.06.028.
Adiponectin, a novel adipocytokine produced exclusively in the adipose tissue, plays a major role in the development of metabolic syndrome, type 2 diabetes mellitus, and related cardiovascular (CV) diseases. However, information is scant regarding the association of adiponectin with measures of CV risk in young adults. This aspect was examined in a biracial (black-white) community-based sample of 1153 individuals (mean age, 36.2 years; 70% white, 43% male) who participated in the Bogalusa Heart Study. Adiponectin levels showed race (white > black, P < .0001) and sex (female > male, P < .0001) differences, and correlated significantly in a beneficial manner to measures of obesity (body mass index, waist circumference, and abdominal height), mean arterial blood pressure, lipoprotein variables (low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides), measures of glucose homeostasis (insulin, glucose, homeostasis model assessment of insulin resistance [HOMA-IR]), and uric acid, after adjusting for age, race, sex, and cigarette smoking. In multivariate analysis that used either body mass index or abdominal height as a measure of general and visceral adiposity in 2 separate models, HOMA-IR was the major contributor explaining 18.4% and 18.1% of the variance, respectively. There was a significant interaction between abdominal height and HOMA-IR on adiponectin level in that the inverse association between adiponectin and insulin resistance was pronounced at higher level of visceral adiposity. Furthermore, adiponectin levels decreased with increasing number of metabolic syndrome risk factors defined by the National Cholesterol Education Program Adult Treatment Panel III (P for trend <.0001). Moreover, adiponectin levels were low among those with positive parental histories of coronary heart disease (P = .03), hypertension (P = .04), and type 2 diabetes mellitus (P = .01), considered as surrogate measures of risk. These findings, by showing an inverse association of adiponectin with insulin resistance, visceral adiposity, and related metabolic syndrome, and also with positive parental histories of coronary heart disease, hypertension, and type 2 diabetes mellitus, underscore the value of adiponectin in CV and type 2 diabetes mellitus risk assessments in young adults.
脂联素是一种仅在脂肪组织中产生的新型脂肪细胞因子，在代谢综合征、2型糖尿病及相关心血管疾病的发生发展中起主要作用。然而，关于脂联素与年轻成年人心血管风险指标之间关联的信息却很少。在参加博加卢萨心脏研究的1153名个体（平均年龄36.2岁；70%为白人，43%为男性）组成的基于社区的双种族（黑-白）样本中，对这一方面进行了研究。脂联素水平存在种族差异（白人>黑人，P<0.0001）和性别差异（女性>男性，P<0.0001），在调整年龄、种族、性别和吸烟因素后，脂联素水平与肥胖指标（体重指数、腰围和腹围）、平均动脉血压、脂蛋白变量（低密度脂蛋白胆固醇、高密度脂蛋白胆固醇和甘油三酯）、葡萄糖稳态指标（胰岛素、血糖、胰岛素抵抗稳态模型评估[HOMA-IR]）以及尿酸呈显著的有益相关性。在两个独立模型中，分别使用体重指数或腹围作为总体和内脏肥胖指标的多变量分析中，HOMA-IR是主要贡献因素，分别解释了18.4%和18.1%的变异。腹围和HOMA-IR对脂联素水平存在显著交互作用，即在内脏肥胖程度较高时，脂联素与胰岛素抵抗之间的负相关更为明显。此外，根据美国国家胆固醇教育计划成人治疗小组第三次报告定义的代谢综合征风险因素数量增加，脂联素水平降低（趋势P<0.0001）。此外，在有冠心病（P=0.03）、高血压（P=0.04）和2型糖尿病（P=0.01）阳性家族史的人群中，脂联素水平较低，这些被视为风险的替代指标。这些发现表明脂联素与胰岛素抵抗、内脏肥胖及相关代谢综合征呈负相关，同时也与冠心病、高血压和2型糖尿病的阳性家族史相关，强调了脂联素在年轻成年人心血管和2型糖尿病风险评估中的价值。
